Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza

Antiviral Therapy

Volumn 8, Issue 3, 2003, Pages 183-190

  Ison, Michael G ^a   Gnann, John W ^b   Nagy Agren, Stephanie ^c   Treanor, John ^d   Paya, Carlos ^e   Steigbigel, Roy ^f   Elliott, Michael ^g   Weiss, Heidi L ^b   Hayden, Frederick G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e MAYO CLINIC   (United States)

^f STONY BROOK UNIVERSITY   (United States)

^g GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIMANTADINE; ZANAMIVIR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HOSPITAL PATIENT; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; KAPLAN MEIER METHOD; LENGTH OF STAY; MALE; MONOTHERAPY; NEBULIZATION; OXYGEN BREATHING; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSTERNAL PAIN; VIRUS RESISTANCE; VIRUS SHEDDING;

EID: 0042656406     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.1177/135965350300800301     Document Type: Article

References (27)

1. Simonsen L, Fukuda K, Schonberger LB & Cox NJ. The impact of influenza epidemics on hospitalizations. Journal of Infectious Diseases 2000; 181:831-837.
2. Barker WH & Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. Archives of Internal Medicine 1982; 142:85-89.
3. Couch RB & Jackson GG. Antiviral agents in influenza. Summary of Influenza Workshop VIII. Journal of Infectious Diseases 1976; 134:516-527.
4. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O & Wightman K. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. New England Journal of Medicine 1997; 337:874-880.
5. Management of Influenza in the Southern Hemisphere Trial (MIST). Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. MIST Study Group. Lancet 1998; 352:1877-1881.
6. Osterhaus ADME, Tisdale M & Elliott M. A double blind randomized trial of zanamivir in the treatment of acute influenza-clinical and virological efficacy results. 38th Interscience Conference on Antimicrobial Agents & Chemotherapy, 1998, San Diego, Calif., USA.
7. Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, Elliott M, Keene ON & Man CY. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. Journal of Infectious Diseases 1999; 180:254-261.
8. Boivin G, Goyette N, Hardy I, Aoki F, Wagner A & Trottier S. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. Journal of Infectious Diseases 2000; 181:1471-1474.
9. Makela MJ, Pauksens K, Rostila T, Fleming DM, Man CY, Keene ON & Webster A. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. Journal of Infection 2000; 40:42-48.
10. Kaiser L, Keene ON, Hammond JM, Elliott M & Hayden FG. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Archives of Internal Medicine 2000; 160:3234-3240.
11. Murphy KR, A. E, Pauksen K, Stein WJ, Tellier G, Watts R, Léophonte P, Sharp SJ & Loeschel E. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled multicentre study. Clinical Drug Investigation 2000; 20:337-349.
12. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P & Mills RG. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group [see comments]. Journal of the American Medical Association 2000; 283:1016-1024.
13. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N & Ward P. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355:1845-1850.
14. Stokes CE, Bernstein JM, Kyger SA & Hayden FG. Rapid diagnosis of influenza A and B by 24-h fluorescent focus assays. Journal of Clinical Microbiology 1988; 26:1263-1266.
15. Mills RD, Cain KJ & Woods GL. Detection of influenza virus by centrifugal inoculation of MDCK cells and staining with monoclonal antibodies. Journal of Clinical Microbiology 1989; 27:2505-2508.
16. Waner JL, Todd SJ, Shalaby H, Murphy P & Wall LV. Comparison of Directigen FLU-A with viral isolation and direct immunofluorescence for the rapid detection and identification of influenza A virus. Journal of Clinical Microbiology 1991; 29:479-482.
17. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y & Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. Journal of Infectious Diseases 2001; 183:523-531.
18. Klimov AI, Rocha E, Hayden FG, Shult PA, Roumillat LF & Cox NJ. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. Journal of Infectious Diseases 1995; 172:1352-1355.
19. Rollins BS, Elkhatieb AH & Hayden FG. Comparative anti-influenza virus activity of 2′-deoxv-2′-fluororibosides in vitro. Antiviral Research 1993; 21:357-368.
20. Englund JA, Champlin RE, Wyde PR, Kantarjian H, Atmar RL, Tarrand J, Yousuf H, Regnery H, Klimov AI, Cox NJ & Whimbey E. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clinical Infectious Diseases 1998; 26:1418-1424.
21. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC & Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. Journal of Infectious Diseases 1998; 178:1257-1262.
22. Kent RS. Important revisions to safety labeling for Relenza (zanamivir for inhalation). Letter to Physicians July 2000. 2000; Research Triangle Park, NC, USA: Glaxo Wellcome. http://www.fda.gov/medwatch/safety/22000/relenz.htm.
23. Monto AS, Moult AB & Sharp SJ. Effect of zanamivir on duration and resolution of influenza symptoms. Clinical Therapeutics 2000; 22:1294-1305.
24. Van Voris LP, Betts RF, Hayden FG, Christmas WA & Douglas RG Jr. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. Journal of the American Medical Association 1981; 245:1128-1131.
25. Betts RF, Treanor JJ, Graman PS, Bentley DW & Dolin R. Antiviral agents to prevent or treat influenza in the elderly. Journal of Respiratory Diseases 1987; s56-s59.
26. Hayden FG. Combination antiviral therapy for respiratory virus infections. Antiviral Research 1996; 29:45-48.
27. Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ, Hammond JM, Sharp SJ & Ossi MJ for the Zanamivir Family Study G. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. New England Journal of Medicine 2000; 343:1282-1289.